RankingsPricing
  1. US-listed companies
  2. ACADIA PHARMACEUTICALS INC
  3. Financials
  4. Stock-based compensation

ACADIA PHARMACEUTICALS INCACAD

Market cap
$3.9B
P/E ratio
SummaryFinancials
Period EndStock-based compensation (Million USD)YoY (%)
Dec 31, 202467+0.95%
Dec 31, 202366-2.61%
Dec 31, 202268+7.21%
Dec 31, 202164-24.65%
Dec 31, 202084+2.62%
Dec 31, 201982+0.86%
Dec 31, 201882+7.99%
Dec 31, 201776+36.67%
Dec 31, 201655+37.50%
Dec 31, 201540+150.60%
Dec 31, 201416+180.84%
Dec 31, 20136+195.91%
Dec 31, 20122+20.78%
Dec 31, 20112

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)